Cardinal Health (NYSE:CAH) released its Q4 results today, surpassing Street expectations. The adjusted earnings per share (EPS) stood at $1.55, representing a significant growth from the previous year's figure of $1.05. This exceeded the Street estimate of $1.49.

The company's revenue also exhibited a strong upward trajectory, reaching a total of $53.45 billion. This marked a 13% year-over-year increase and surpassed the projected revenue of $52.7 billion. Within this, the pharmaceutical revenue segment reached an impressive $49.7 billion, showcasing a 15% year-over-year rise and surpassing the projected revenue of $48.96 billion.

In light of this exceptional performance during Q4, Cardinal Health has revised its non-GAAP EPS guidance for the fiscal year 2024. The new projected range stands at $6.50 to $6.75, up from the previous range of $6.45 to $6.70.